Anemic Pipeline at Dynavax – Analyst Blog
Source: http://www.zacks.com/stock/news/21570/Anemic+Pipeline+at+Dynavax+-+Analyst+BlogPosted on Monday, June 29th, 2009 | In Market Commentary, Stocks to Watch
Dynavax Technologies Corp. (DVAX) is a biopharmaceutical company focused on drug development for the treatment and prevention of various infectious and inflammatory diseases.
The company was recently hit hard by a couple of major negative events: the clinical hold and the subsequent termination of the partnership with Merck (MRK) for Heplisav, a late stage candidate for Hepatitis B vaccine, and the discontinuation of the Tolamba program for allergy. Currently, Dynavax is in active discussions with regulatory agencies to resolve the FDA’s clinical hold on Heplisav and identify an appropriate path for its further development and approval in the United States, Europe, and the rest of the world.
The deal with Glaxo is a big positive
In 4Q08, Dynavax and GlaxoSmithKline (GSK) signed a worldwide strategic alliance to discover, develop and commercialize novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases. TLRs are key receptors of the innate immune system that can induce strong inflammatory responses.
The company believes that the alliance with GSK, which could be worth up to $800 million, provides an opportunity to develop an entirely new product franchise.
Flu vaccine program still in early stage
The universal flu vaccine which Dynavax is developing under a global supply and option agreement with Novartis (NVS) has the potential to be a prominent player in the market for seasonal influenza vaccines. Encouraging preclinical data have been presented at various medical conferences. However, since the candidate is in preclinical stage, it ceases to be a current option to deal with the global swine flu breakout.
No product on the horizon
Even though, we were pleased to hear about the company’s agreement with Glaxo, we remain concerned that the company has no visible drug candidate under development. We don’t think that DVAX can afford and/or has an immediate plan to acquire any late stage drug candidate under the current financial conditions. Therefore, we do not recommend the shares currently and have a Hold rating.
Read the full analyst report on “DVAX”
Read the full analyst report on “GSK”
Read the full analyst report on “MRK”
Read the full analyst report on “NVS”
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
Allergy, Europe, Fda, Glaxo;, Glaxosmithkline, Hepatitis B;, Heplisav;, Influenza, late stage candidate, Market Commentary, Merck, Merck & Co. Inc., Novartis, prominent player, stage candidate, stage drug candidate, Stocks to Watch, strong inflammatory, treatment of immuno-inflammatory diseases, United States, USD, Vaccines, visible drug candidate, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.